SAVARA ANNOUNCES PRICING OF $100.0

SAVARA ANNOUNCES PRICING OF $100.0 MILLION UNDERWRITTEN OFFERING OF COMMON STOCK

LANGHORNE, Pa., June 28, 2024 Savara Inc. (Nasdaq: SVRA), a clinical stage biopharmaceutical company focused on rare respiratory diseases,

today announced the pricing of an underwritten offering of 26,246,720 shares of its common stock at a price of $3.81 per share before deducting underwriting discounts and commissions, for total gross proceeds of approximately $100.0 million.

All of the securities to be sold in the offering are being sold by Savara. The offering included the following investors: Bain Capital Life Sciences, Farallon Capital Management, Frazier Life Sciences, Wellington Management, Nantahala Capital, TCGX

and First Light Asset Management, among others. The offering is expected to close on July 1, 2024, subject to the satisfaction of customary closing conditions.

Jefferies, Piper Sandler and Guggenheim Securities are acting as joint book-running managers for the offering. Oppenheimer & Co. is acting as the

lead manager for the offering.

These securities were offered by Savara pursuant to its existing shelf registration statement (File No. 333-279274) filed with the Securities and Exchange Commission (SEC) on May 9, 2024 and declared effective on May 21, 2024. A prospectus supplement describing the terms of the offering will be

filed with the SEC and will form a part of the effective registration statement. Copies of the prospectus supplement and accompanying prospectus relating to the offering may be obtained by contacting Jefferies LLC, Attention: Equity Syndicate

Prospectus Department, 520 Madison Avenue, New York, New York 10022, by telephone at (877) 821-7388, or by email at Prospectus_Department@Jefferies.com, Piper Sandler & Co., Attention:

Prospectus Department, 800 Nicollet Mall, J12S03, Minneapolis, Minnesota 55402, by telephone at (800) 747-3924, or by email at prospectus@psc.com, or Guggenheim Securities, LLC, Attention: Equity

Syndicate Department, 330 Madison Avenue, 8th Floor, New York, New York 10017, by telephone at (212) 518-9544, or by email at GSEquityProspectusDelivery@guggenheimpartners.com. An electronic copy of the prospectus supplement and accompanying

prospectus relating to the offering will be available on the SEC website at www.sec.gov.

This press release does not constitute an offer to sell

or the solicitation of offers to buy any securities of Savara, and shall not constitute an offer, solicitation, or sale of any security in any state or jurisdiction in which such offer, solicitation or sale would be unlawful prior to registration or

qualification under the securities laws of any such state or jurisdiction.

Savara is a clinical stage biopharmaceutical company focused on rare respiratory diseases. Savara s lead program, molgramostim nebulizer solution, is an

inhaled granulocyte-macrophage colony-stimulating factor (GM-CSF) in Phase 3 development for autoimmune pulmonary alveolar proteinosis (aPAP). Molgramostim is delivered via an investigational eFlow Nebulizer System (PARI Pharma GmbH) specifically developed for inhalation of a large molecule. Savara s management team has significant experience in rare respiratory diseases and pulmonary

medicine, identifying unmet needs, and effectively advancing product candidates to approval and commercialization.

Forward-Looking Statements

Savara cautions you that statements in this press release that are not a description of historical fact are forward-looking statements within the meaning of

the Private Securities Litigation Reform Act of 1995. Forward-looking statements may be identified by the use of words referencing future events or circumstances such as expect, intend, plan,

anticipate, believe, and will, among others. Such statements include, but are not limited to, statements related to the offering, including the timing of the offering and size. Savara may not actually achieve any

of the matters referred to in such forward-looking statements, and you should not place undue reliance on these forward-looking statements. Because such statements are subject to risks and uncertainties, actual results may differ materially from

those expressed or implied by such forward-looking statements. These forward-looking statements are based upon Savara s current expectations and involve assumptions that may never materialize or may prove to be incorrect. Actual results and the

timing of events could differ materially from those anticipated in such forward-looking statements as a result of various risks and uncertainties, which include, without limitation, stock market conditions, Savara s ability to satisfy the

conditions to closing in the underwriting agreement, Savara s ability to complete the offering, the risks and uncertainties relating to the impact of widespread health concerns impacting healthcare providers or patients, disruptions or

inefficiencies in the supply chain and geopolitical conditions on Savara s business and operations, the outcome of Savara s ongoing and planned clinical trials for Savara s product candidate, the ability to project future cash

utilization and reserves needed for contingent future liabilities and business operations, the availability of sufficient resources for Savara s operations and to conduct or continue planned clinical development programs, the ability to obtain

the necessary patient enrollment for Savara s product candidate in a timely manner, the ability to successfully develop Savara s product candidate, the risks associated with the process of developing, obtaining regulatory approval for and

commercializing drug candidates such as molgramostim that are safe and effective for use as human therapeutics, and the timing and ability of Savara to raise additional capital as needed to fund continued operations. All forward-looking statements

are expressly qualified in their entirety by these cautionary statements. For a detailed description of Savara s risks and uncertainties, you are encouraged to review Savara s documents filed with the SEC including its recent filings on

Form 8-K, Form 10-K and Form 10-Q. You are cautioned not to place undue reliance on forward-looking statements, which speak only

as of the date on which they were made. Savara undertakes no obligation to update such statements to reflect events that occur or circumstances that exist after the date on which they were made, except as may be required by law.

Anne Erickson (anne.erickson@savarapharma.com)